Advertisement
Advertisement

ESPR

ESPR logo

Esperion Therapeutics, Inc.

3.40
USD
Sponsored
+0.22
+7.08%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

3.40

-0.01
-0.29%

ESPR Earnings Reports

Positive Surprise Ratio

ESPR beat 23 of 40 last estimates.

57%

Next Report

Date of Next Report
Feb 24, 2026
Estimate for Q4 25 (Revenue/ EPS)
$182.64M
/
$0.26
Implied change from Q3 25 (Revenue/ EPS)
+109.18%
/
-262.50%
Implied change from Q4 24 (Revenue/ EPS)
+164.26%
/
-336.36%

Esperion Therapeutics, Inc. earnings per share and revenue

On Nov 06, 2025, ESPR reported earnings of -0.16 USD per share (EPS) for Q3 25, missing the estimate of -0.05 USD, resulting in a -183.69% surprise. Revenue reached 87.31 million, compared to an expected 79.36 million, with a 10.02% difference. The market reacted with a -14.97% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 11 analysts forecast an EPS of 0.26 USD, with revenue projected to reach 182.64 million USD, implying an decrease of -262.50% EPS, and increase of 109.18% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Esperion Therapeutics, Inc. reported EPS of -$0.16, missing estimates by -183.69%, and revenue of $87.31M, 10.02% above expectations.
The stock price moved down -14.97%, changed from $2.94 before the earnings release to $2.50 the day after.
The next earning report is scheduled for Feb 24, 2026.
Based on 11 analysts, Esperion Therapeutics, Inc. is expected to report EPS of $0.26 and revenue of $182.64M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement